No headlines found.
No press releases found.
No news found.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.
China Pharma Holdings trades on the AMEX stock market under the symbol CPHI.
As of February 6, 2026, CPHI stock price climbed to $0.69 with 23,920 million shares trading.
CPHI has a beta of 0.21, meaning it tends to be less sensitive to market movements. CPHI has a correlation of 0.00 to the broad based SPY ETF.
CPHI has a market cap of $3.48 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CPHI traded as high as $56.35 and as low as $.61.
CPHI has underperformed the market in the last year with a price return of -66.5% while the SPY ETF gained +15.1%. CPHI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -56.8% and -44.1%, respectively, while the SPY returned +3.3% and +0.2%, respectively.
CPHI support price is $.57 and resistance is $.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CPHI shares will trade within this expected range on the day.
